CRISPR/Cas基因组编辑在三阴性乳腺癌中的现状和未来方向。
CRISPR/Cas genome editing in triple negative breast cancer: Current situation and future directions.
发表日期：2023 Feb 07
作者：
Leilei Fu, Zixiang Li, Yueting Ren, Haiyang Yu, Bo Liu, Yuling Qiu
来源：
BIOCHEMICAL PHARMACOLOGY
摘要：
三重阴性乳腺癌（TNBC）已广为人知地与癌基因和肿瘤抑制基因的异常表达密切相关。虽然已经发现了几种TNBC的病原突变，但当前的治疗策略通常是针对症状缓解而不是纠正DNA序列中的突变。值得注意的是，团簇规则间隔短异向重复序列（CRISPR）/CRISPR相关蛋白（Cas）逐渐被认为是一种具有潜在治疗应用于人类肿瘤包括TNBC的突破性基因编辑工具。因此，在本次综述中，我们重点总结了TNBC的分子亚型，以及CRISPR系统及其在TNBC治疗中的潜在应用。此外，我们进一步讨论了利用CRISPR/Cas系统进行精确诊断TNBC的几种新兴策略，以及CRISPR/Cas系统的局限性。这些发现将证明CRISPR/Cas系统不仅是TNBC中有效的基因组编辑工具，而且是未来治疗目的的有前途的策略。版权所有©2023 Elsevier Inc.。
Triple negative breast cancer (TNBC) has been well-known to be closely associated with the abnormal expression of both oncogenes and tumor suppressors. Although several pathogenic mutations in TNBC have been identified, the current therapeutic strategy is usually aimed at symptom relief rather than correcting mutations in the DNA sequence. Of note, clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein (Cas) has been gradually regarded as a breakthrough gene-editing tool with potential therapeutic applications in human cancers, including TNBC. Thus, in this review, we focus on summarizing the molecular subtypes of TNBC, as well as the CRISPR system and its potential applications in TNBC treatment. Moreover, we further discuss several emerging strategies for utilizing the CRISPR/Cas system to aid in the precise diagnosis of TNBC, as well as the limitations of the CRISPR/Cas system. Taken together, these findings would demonstrate that CRISPR/Cas system is not only an effective genome editing tool in TNBC, but a promising strategy for the future therapeutic purposes.Copyright © 2023 Elsevier Inc. All rights reserved.